Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emerging threat of Oropouche virus: Clinical features, experimental models, and virulence.

Virulence·2026
Same author

Prevention of endophthalmitis with cataract surgery<i>: where are we now 20 years after the ESCRS Study?</i>

The British journal of ophthalmology·2026
Same author

Oropouche virus NSs protein suppresses host transcription by targeting the RNA polymerase II RPB1 protein.

Journal of virology·2025
Same author

Small Molecule Inhibitors of <i>Mycobacterium tuberculosis</i> Topoisomerase I Identified by Machine Learning and In Vitro Assays.

International journal of molecular sciences·2024
Same author

NGT: Generative AI with Synthesizability Guarantees Discovers MC2R Inhibitors from a Tera-Scale Virtual Screen.

Journal of medicinal chemistry·2024
Same author

Distinct Pathological Changes in Preweaning Mice Infected with Live-Attenuated Rift Valley Fever Virus Strains.

Viruses·2024

Related Experiment Video

Updated: Jun 23, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.2K

Computer-Selected Antiviral Compounds: Assessing In Vitro Efficacies against Rift Valley Fever Virus.

Cigdem Alkan1, Terrence O'Brien2, Victor Kenyon3

  • 1Department of Pathology, The University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.

Viruses
|January 23, 2024
PubMed
Summary

Researchers identified novel antiviral compounds effective against Rift Valley fever virus by targeting its Gc fusion mechanism. AI-driven screening accelerated the discovery of these promising candidates for human and livestock health.

Keywords:
AI-based computational drug discoveryArumowot virusDabie bandavirusGc fusion loopHeartland virusRift Valley feversmall molecule compound

More Related Videos

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
09:04

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

12.6K
High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication
10:16

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication

Published on: October 30, 2021

3.7K

Related Experiment Videos

Last Updated: Jun 23, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.2K
In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
09:04

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

12.6K
High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication
10:16

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication

Published on: October 30, 2021

3.7K

Area of Science:

  • Virology
  • Drug Discovery
  • Computational Biology

Background:

  • Rift Valley fever is a mosquito-borne zoonotic viral disease with no current human vaccines or treatments.
  • The virus poses a significant threat to human and livestock populations.
  • Targeting viral entry mechanisms is a key strategy for developing new antiviral therapies.

Purpose of the Study:

  • To evaluate the in vitro efficacy of small molecule compounds against Rift Valley fever virus (RVFV).
  • To identify compounds that inhibit the RVFV Gc fusion mechanism.
  • To validate artificial intelligence (AI)-based virtual screening for antiviral drug discovery.

Main Methods:

  • Virtual screening of millions of small molecules using a structure-based AI bioactivity predictor.
  • In vitro antiviral assays using Vero cells infected with RVFV MP-12 strain.
  • Testing compound efficacy at different time points relative to viral infection (pretreatment vs. post-infection).
  • Assessing cross-activity against other viruses like Arumowot virus and tick-borne bandaviruses.

Main Results:

  • Three out of 94 selected compounds demonstrated significant inhibition of RVFV replication in vitro.
  • Inhibitory effect was observed when compounds were used as a pretreatment, blocking viral entry.
  • Compounds did not inhibit viral RNA replication when administered post-infection.
  • Significant inhibition was observed against Arumowot virus (a phlebovirus), but not against tick-borne bandaviruses.

Conclusions:

  • AI-based virtual high-throughput screening is a viable and rational approach for identifying antiviral candidates against RVFV.
  • The identified compounds show promise as potential therapeutics by targeting the viral Gc fusion mechanism.
  • This study provides a foundation for further development of treatments for Rift Valley fever and related bunyaviruses.